- Home
- BJRI vs TSHA Comparison
BJRI vs TSHA Comparison
Compare BJRI & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BJRI | TSHA |
|---|---|---|
| Founded | 1978 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BJRI | TSHA |
|---|---|---|
| Price | $59.25 | $4.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $75.14 | $13.00 |
| AVG Volume (30 Days) | 309.2K | ★ 2.8M |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 208.57 | 5.56 |
| EPS | ★ 1.27 | N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | $4.14 | N/A |
| Revenue Next Year | $4.03 | $1,023.00 |
| P/E Ratio | $46.54 | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $28.46 | $3.69 |
| 52 Week High | $74.60 | $7.30 |
Technical Indicators
Market Signals| Indicator | BJRI | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 38.99 |
| Support Level | $58.35 | $4.37 |
| Resistance Level | $62.68 | $5.07 |
| Average True Range (ATR) | 2.01 | 0.24 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 37.46 | 37.78 |
Price Performance
Historical ComparisonAbout BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.